Browsing Tag
XDEMVY
2 posts
Tarsus completes Alkeus acquisition as Phase 3 retina strategy takes shape
Tarsus Pharmaceuticals has completed its acquisition of Alkeus Pharmaceuticals, paying $450 million upfront for a Phase 3 Stargardt disease program that could expand a fast-growing eye-care business beyond XDEMVY.
Tarsus Pharmaceuticals (NASDAQ: TARS) to add Alkeus in $800m eye pipeline deal
Tarsus lines up an $800m Alkeus deal and a $125m PIPE to enter Stargardt disease, but a 2029 readout and Belite Bio's lead still gate the retina thesis.